Public clinical trial registration: <http://clinicaltrials.gov/show/NCT00017953>. Look AHEAD: Action for Health in Diabetes.

Introduction {#jbm410086-sec-0002}
============

Osteoporotic fracture is a serious and costly clinical problem associated with type 2 diabetes.[1](#jbm410086-bib-0001){ref-type="ref"} Overweight or obese individuals with diabetes are often prescribed weight loss to improve glycemic control,[2](#jbm410086-bib-0002){ref-type="ref"} yet weight loss may further augment fracture risk.[3](#jbm410086-bib-0003){ref-type="ref"} Indeed, recent results from the Look AHEAD study suggest 6% to 9% weight loss achieved and maintained over nearly a decade is associated with significantly reduced bone mineral density (BMD)[4](#jbm410086-bib-0004){ref-type="ref"}, [5](#jbm410086-bib-0005){ref-type="ref"} and increased risk of hip, pelvis, and upper arm fracture.[6](#jbm410086-bib-0006){ref-type="ref"} Data also suggest that bone mass is not recovered when lost weight is regained,[7](#jbm410086-bib-0007){ref-type="ref"}, [8](#jbm410086-bib-0008){ref-type="ref"} raising concern about the long‐term impact of repeated weight loss attempts on bone health. Given the well‐known recidivism of obesity,[9](#jbm410086-bib-0009){ref-type="ref"} surprisingly little is known about the effect of weight regain or weight cycling on incident fracture risk. Limited observational data do link weight variability[10](#jbm410086-bib-0010){ref-type="ref"}, [11](#jbm410086-bib-0011){ref-type="ref"} and self‐reported weight cycling[12](#jbm410086-bib-0012){ref-type="ref"}, [13](#jbm410086-bib-0013){ref-type="ref"} with higher fracture incidence; however, the long‐term impact of objectively measured patterns of weight change on fracture risk following a structured weight loss program has not been assessed. Data collected in the Look AHEAD (Action for Health in Diabetes; [Clinicaltrials.gov](http://Clinicaltrials.gov) Identifier: NCT00017953) study provide a unique opportunity to address this question. Using measured weights over a 4‐year period, we aimed to explore associations of three patterns of weight change following intentional weight loss (ie, weight regainers, weight cyclers, and continued losers/maintainers) on fracture risk and change in BMD occurring over the next decade.

Materials and Methods {#jbm410086-sec-0003}
=====================

The Look AHEAD Study was a multicenter, randomized controlled trial designed to determine whether intentional weight loss reduces cardiovascular morbidity and mortality in overweight individuals with type 2 diabetes. The study was approved by local Institutional Review Boards and all participants provided informed consent. Details on the study design[14](#jbm410086-bib-0014){ref-type="ref"} and baseline characteristics[15](#jbm410086-bib-0015){ref-type="ref"} have previously been published, along with treatment effects on BMD[4](#jbm410086-bib-0004){ref-type="ref"}, [5](#jbm410086-bib-0005){ref-type="ref"} and fracture.[6](#jbm410086-bib-0006){ref-type="ref"} The primary analysis of this work includes 1885 (of 2570) Intensive Lifestyle Intervention (ILI) participants who were successful at losing any weight during the first year of the study (*n* = 2290) and had at least two follow‐up weights (excluded *n* = 301), no fractures prior to year 4 (excluded *n* = 77), and non‐missing covariate data (excluded *n* = 27).

Exposure assessment: weight patterns {#jbm410086-sec-0004}
------------------------------------

Weight was measured annually by certified clinic staff, masked to intervention assignment, using a Tanita BWB 800 digital scale (Tanita, Willobrook, IL). Based on the first 3 years of follow‐up (years 1 through 4), participants were classified into three categories: (i) weight regainers, (ii) weight cyclers, and (iii) continued losers/maintainers, using patterns previously employed in the Look AHEAD study[16](#jbm410086-bib-0016){ref-type="ref"} and a clinically meaningful[17](#jbm410086-bib-0017){ref-type="ref"} ±3% weight change threshold.

Primary outcome assessment: incident fracture {#jbm410086-sec-0005}
---------------------------------------------

Centrally adjudicated incident fractures included in this analysis occurred between year 4 and the end of the Look AHEAD‐Continuation phase, with maximum follow‐up time of 13.2 years (median, 11.5 years). As described,[6](#jbm410086-bib-0006){ref-type="ref"} overall fracture included adjudicated hand (not finger), lower arm or wrist, elbow, upper arm, shoulder, clavicle, spine or back, tailbone, pelvis, hip, upper leg, knee, lower leg or ankle, and foot (not toe); we also examined a composite variable for the first occurrence of hip, pelvis, or upper arm fracture (not including clavicle or scapula).

Secondary outcome assessment: change in regional BMD {#jbm410086-sec-0006}
----------------------------------------------------

Total hip, femoral neck, and lumbar spine BMD were assessed at five of the 16 Look AHEAD clinical sites using Hologic fan beam densitometers (DXA), as described.[4](#jbm410086-bib-0004){ref-type="ref"}, [5](#jbm410086-bib-0005){ref-type="ref"} The BMD study sample was derived using the same inclusion criteria described for the incident fracture sample, and limited to participants with baseline and year 4 (*n* = 468) or year 8 (*n* = 354) regional DXA scans.

Covariates {#jbm410086-sec-0007}
----------

Self‐reported characteristics (ie, age, gender, race/ethnicity, smoking status, and alcohol consumption) and medical history were assessed using standardized questionnaires. Height was measured in duplicate using a stadiometer and body mass index (BMI) was calculated as weight in kilograms divided by height in meters squared. Participants brought current prescription medications to update medication records, with bone negative medications defined as: loop diuretics, selective serotonin reuptake inhibitors (SSRIs), thyroid hormones, oral steroids such as prednisone, tricyclic antidepressants, and thiazolidinedione (TZDs); and bone positive medications defined as: androgens (anabolic steroids), calcium, antacids containing calcium, and antiresorptive agents such as bisphosphonates, calcitonin nasal spray, estrogens, and selective estrogen receptor modulators (SERMs). Fasting blood specimens were analyzed by the Central Biochemistry Laboratory (Northwest Lipid Research Laboratories, University of Washington, Seattle, WA, USA) using standardized laboratory procedures for measuring glycated hemoglobin (HbA1c). Depressive symptoms were assessed using the Beck Depression Inventory (BDI; score range 0 to 63), with higher scores indicating more symptoms of depression.

Statistical methods {#jbm410086-sec-0008}
-------------------

Descriptive statistics were calculated overall and by weight pattern classification at baseline. Cox proportional hazards models, both unadjusted and adjusted for relevant baseline covariates (including: age category, gender, race, BMI category, bone‐positive medication use, and bone‐negative medication use, history of arthritis, HbA1c, smoking status, alcohol consumption, diabetes duration, and BDI score) were performed for incident overall and hip, pelvis, or upper arm fracture outcomes. Because fracture risk is elevated in older women, a formal test of interaction between age, gender, and weight pattern category was conducted to inform whether stratified analyses should be performed. Differences in hip, femoral neck, and lumbar spine BMD at years 4 and 8 were assessed in a subset of participants using linear regression models, adjusting for the same covariates described above plus baseline value of the outcome, and presented as least square means and standard errors. All statistical analyses were executed using SAS version 9.4 (SAS Institute, Inc., Cary, NC, USA).

Results {#jbm410086-sec-0009}
=======

Participant characteristics {#jbm410086-sec-0010}
---------------------------

Baseline descriptive characteristics, detailed by group and overall, are presented in Table [1](#jbm410086-tbl-0001){ref-type="table"}. As shown, average age was 58.5 ± 6.7 years, 58% were female, 64% were white, and BMI was 35.7 ± 6.0 kg/m^2^. Fifty‐eight percent, 22% and 20% of participants were classified as weight regainers, weight cyclers, and continued losers/maintainers, respectively. On average, by the year 4 visit, regainers gained 8.3 ± 5.5 kg, weight cyclers gained 1.1 ± 7.0 kg, and continued losers/maintainers lost 2.9 ± 6.0 kg from the year 1 weight. Weight cyclers were more likely to be between the ages of 50 and 59 years, female, Hispanic, and using bone‐positive medications, than other categories (all *p* ≤ 0.02). Participants in the DXA analyses were more likely to be female (*p* \< 0.01), of ethnic minority (*p* \< 0.01), and slightly younger (*p* = 0.05) when compared to the main analysis sample; however, the distribution of weight pattern categories within the DXA subset was similar to the larger study sample (data not shown).

###### 

Baseline Characteristics Overall and by Weight Pattern Category Among Look AHEAD Participants Randomized to Intensive Lifestyle Intervention Who Lost Weight in the First Year

  Characteristic                                                                    Overall      Weight regainer   Weight cycler   Continued loser or maintainer   *p*
  --------------------------------------------------------------------------------- ------------ ----------------- --------------- ------------------------------- --------
  Total, *n* (%)                                                                    1885 (100)   1086 (58)         418 (22)        381 (20)                        
  Age category (years), *n* (%)                                                                                                                                    0.02
  \<50 years                                                                        205 (11)     117 (11)          52 (12)         36 (9)                          
  50--59 years                                                                      890 (47)     495 (46)          223 (53)        172 (45)                        
  60--69 years                                                                      669 (35)     407 (37)          121 (29)        141 (37)                        
  70+ years                                                                         121 (6)      67 (6)            22 (5)          32 (8)                          
  Female gender, *n* (%)                                                            1090 (58)    597 (55)          286 (68)        207 (54)                        \<0.01
  Race/ethnicity, *n* (%)                                                                                                                                          \<0.01
  African American                                                                  305 (16)     162 (15)          65 (16)         78 (20)                         
  Hispanic                                                                          229 (12)     119 (11)          61 (15)         49 (13)                         
  White                                                                             1214 (64)    745 (69)          259 (62)        210 (55)                        
  Other                                                                             137 (7)      60 (6)            33 (8)          44 (12)                         
  BMI category (kg/m^2^), *n* (%)                                                                                                                                  0.05
  25--27                                                                            59 (3)       30 (3)            12 (3)          17 (4)                          
  27--30                                                                            251 (13)     149 (14)          43 (10)         59 (15)                         
  30--35                                                                            675 (36)     412 (38)          143 (34)        120 (32)                        
  35--40                                                                            486 (26)     266 (24)          113 (27)        107 (28)                        
  40+                                                                               414 (22)     229 (21)          107 (26)        78 (20)                         
  Bone‐negative medication use, *n* (%)[^a^](#jbm410086-note-0003){ref-type="fn"}   851 (45)     493 (45)          192 (46)        166 (44)                        0.77
  Bone‐positive medication use, *n* (%)[^b^](#jbm410086-note-0004){ref-type="fn"}   471 (25)     261 (24)          125 (30)        85 (22)                         0.03
  Presence of arthritis, *n* (%)                                                    771 (41)     426 (39)          174 (42)        171 (45)                        0.15
  HbA1c (%), mean ± SD                                                              7.2 ± 1.1    7.1 ± 1.1         7.3 ± 1.1       7.3 ± 1.1                       \<0.01
  Smoking status, *n* (%)                                                                                                                                          0.17
  Never                                                                             950 (50)     533 (49)          233 (56)        184 (48)                        
  Past                                                                              852 (45)     506 (46)          168 (40)        178 (47)                        
  Present                                                                           83 (5)       47 (4)            17 (4)          19 (5)                          
  Alcohol consumption, *n* (%)                                                                                                                                     0.08
  None/week                                                                         1279 (68)    720 (66)          295 (71)        264 (69)                        
  1--3/week                                                                         358 (19)     219 (20)          80 (19)         59 (15)                         
  4+/week                                                                           248 (13)     147 (14)          43 (10)         58 (15)                         
  Diabetes duration (years), mean ± SD                                              6.6 ± 6.6    6.6 ± 6.6         6.4 ± 6.7       7.0 ± 6.4                       0.36
  Beck Depression Inventory score (0--63), mean ± SD                                5.3 ± 5.0    5.1 ± 4.9         5.7 ± 5.2       5.2 ± 4.8                       0.14

Weight change pattern during the first 4 years of follow‐up.

SSRI = selective serotonin reuptake inhibitor; TZD = thiazolidinedione; SERM = selective estrogen receptor modulator.

Bone‐negative medications are defined as: loop diuretics, SSRIs, thyroid hormones, oral steroids such as prednisone, tricyclic antidepressants, and TZDs.

Bone‐positive medications are defined as: androgens (anabolic steroids), calcium, antacids containing calcium, and antiresorptive agents such as bisphosphonates, calcitonin nasal spray, estrogens, and SERMs.
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Association between weight patterns and incident fracture {#jbm410086-sec-0011}
---------------------------------------------------------

Over a total of 11.5 years of follow‐up, 217 fractures (men *n* = 63; women *n* = 154) were recorded overall. Figure [1](#jbm410086-fig-0001){ref-type="fig"} presents Kaplan‐Meier curves of incident overall fracture by weight pattern category. There were no statistically significant differences in total incident fracture rates for weight regainers (HR \[95% CI\]: 1.01 \[95% CI, 0.71 to 1.44\]) or weight cyclers (1.02 \[95% CI, 0.68 to 1.53\]) when compared to continued losers/maintainers (*p* = 0.99). Similar results were observed for incident hip, pelvis, or upper arm fracture (data not shown). The interaction between age, gender, and weight pattern category was not significant (*p* = 0.75), thus stratified analyses were not pursued.

![Cumulative hazard curve using predicted values from Cox proportional hazard regression fully‐adjusted model displaying weight pattern category by probability of fracture and years to fracture.](JBM4-3-na-g001){#jbm410086-fig-0001}

Association between weight patterns and regional BMD {#jbm410086-sec-0012}
----------------------------------------------------

As with incident fracture, no significant associations were observed between weight pattern classification and year 4 and year 8 regional BMD at any site. Trends for lower BMD at the femoral neck and total hip were observed in continued losers/maintainers and weight cyclers compared with weight regainers, yet they did not attain statistical significance. Specifically, by year 8, femoral neck BMD was reduced from baseline by −0.050 ± 0.012 g/cm^2^ (−4.5%), −0.055 ± 0.012 g/cm^2^ (−3.9%), and −0.039 ± 0.010 g/cm^2^ (−3.0%) in continued losers/maintainers, weight cyclers, and weight regainers, respectively (*p* = 0.11). Likewise, by year 8, total hip BMD was reduced by −0.046 ± 0.012 g/cm^2^ (−3.9%), −0.042 ± 0.012 g/cm^2^ (−3.3%), and −0.032 ± 0.011 g/cm^2^ (−1.9%) from baseline values in continued losers/maintainers, weight cyclers, and weight regainers, respectively (*p* = 0.21). No signal was observed for change in lumbar spine BMD (continued losers/maintainers: +0.033 ± 0.015 g/cm^2^, weight cyclers: +0.018 ± 0.015 g/cm^2^, and weight regainer: +0.023 ± 0.013 g/cm^2^; *p* = 0.48).

Discussion {#jbm410086-sec-0013}
==========

There is increasing interest in understanding the skeletal effects of obesity and diabetes, particularly in the context of weight loss. As reported, randomization to an intensive lifestyle intervention, resulting in weight loss for most participants, was associated with modest bone loss[4](#jbm410086-bib-0004){ref-type="ref"}, [5](#jbm410086-bib-0005){ref-type="ref"} and increased risk of fractures occurring at the hip, pelvis, and upper arm.[6](#jbm410086-bib-0006){ref-type="ref"} Here we report that, among those randomized to the lifestyle intervention who lost weight during the first year, patterns of weight change in the subsequent 3 years were not associated with incident fracture or significantly reduced BMD; however, data suggest a trend toward lowered BMD at the hip among continued losers/maintainers and weight cyclers, compared to weight regainers.

We are aware of only four studies examining the effect of weight variability[10](#jbm410086-bib-0010){ref-type="ref"}, [11](#jbm410086-bib-0011){ref-type="ref"} or cycling[12](#jbm410086-bib-0012){ref-type="ref"}, [13](#jbm410086-bib-0013){ref-type="ref"} on fracture risk to date, all of which report positive associations. The earliest reports, examining weight variability (defined using the root mean square error) and incident hip fracture, suggest a 50% to 270% increased risk for those in the highest quartile of weight variability, compared to the lowest. More recent studies led by Søgaard and colleagues[12](#jbm410086-bib-0012){ref-type="ref"}, [13](#jbm410086-bib-0013){ref-type="ref"} extend these findings to weight cycling, demonstrating increased risk of forearm fracture in men[12](#jbm410086-bib-0012){ref-type="ref"} and nonvertebral fracture in women[13](#jbm410086-bib-0013){ref-type="ref"} who self‐reported multiple weight loss episodes (ie, ≥4 in men and ≥11 in women). In contrast, relative to continued weight loss or weight loss maintenance, we did not observe an association between a single bout of weight regain or weight cycling on fracture incidence, thereby adding equipoise to a limited evidence base. Certainly, discrepancies may be due to differing definitions used for weight cycling, as well as the lower number of absolute weight cycles possible in our study.

To our knowledge, our study is the first to assess the effect of weight patterns dynamics following *intentional* weight loss on incident fracture; although the effect of weight change following voluntary weight loss on BMD has been assessed in a handful of studies. Some, but not all,[18](#jbm410086-bib-0018){ref-type="ref"}, [19](#jbm410086-bib-0019){ref-type="ref"} studies suggest that the well‐described 2% decline in BMD with 10% weight loss continues progressively despite weight loss maintenance,[20](#jbm410086-bib-0020){ref-type="ref"} and does not return with weight regain.[7](#jbm410086-bib-0007){ref-type="ref"}, [8](#jbm410086-bib-0008){ref-type="ref"} Trends observed in our BMD data are in general agreement with prior reports, although results were nonsignificant. Importantly, if true, these observations suggest that skeletal remodeling is affected by factors other than change in loading forces, and may imply that transient weight loss attempts have lasting catabolic effects on the skeleton.

Strengths of this study include use of objectively measured weights to assess changing weight dynamics following intentional weight loss, as well as adjustment for multiple, relevant covariates. Despite these design strengths, Look AHEAD was not designed to detect differences in incident fracture rates between weight pattern classifications; thus, our analyses may have been underpowered. Certainly, DXA data, which were only available in a subset, are meant to be hypothesis generating, rather than confirmatory. A general limitation in this field of research is the lack of an operational definition for weight cycling. Although we used patterns previously employed in the Look AHEAD study[16](#jbm410086-bib-0016){ref-type="ref"} and a clinically meaningful[17](#jbm410086-bib-0017){ref-type="ref"} ±3% weight change threshold, conclusions may differ by weight pattern category definition used. Last, extrapolation of results should be limited to similar populations, particularly with regard to age and disease status.

In conclusion, in this cohort of overweight and obese adults with type 2 diabetes experiencing intentional weight loss over a year, we did not observe a significant association between subsequent patterns of weight change and incident fracture. Overall, findings temper concerns regarding weight cycling following intentional weight loss on fracture risk, at least in the short term, although certainly more work in this area is needed.
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Look AHEAD Research Group at End of Continuation {#jbm410086-sec-0017}
================================================

Clinical sites {#jbm410086-sec-0018}
--------------
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\*deceased
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*Joslin Diabetes Center*: Edward S. Horton, MD^1^; Sharon D. Jackson, MS, RD, CDE^2^; Osama Hamdy, MD, PhD^3^; A. Enrique Caballero, MD^3^; Sarah Bain, BS; Elizabeth McKinney, BSN, RN; Barbara Fargnoli, MS,RD; Jeanne Spellman, BS, RD; Kari Galuski, RN; Ann Goebel‐Fabbri, PhD; Lori Lambert, MS, RD; Sarah Ledbury, MEd, RD; Maureen Malloy, BS; Kerry Ovalle, MS, RCEP, CDE.

*Beth Israel Deaconess Medical Center*: George Blackburn, MD, PhD^1\*^ Christos Mantzoros, MD, DSc^3^; Ann McNamara, RN.

\*deceased
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[University of Southern California:]{.ul} Anne Peters, MD^1^; Siran Ghazarian, MD^2^; Elizabeth Beale, MD^3^; Kati Konersman, RD, CDE; Brenda Quintero‐Varela; Edgar Ramirez; Gabriela Rios, RD; Gabriela Rodriguez, MA; Valerie Ruelas MSW, LCSW; Sara Serafin‐Dokhan; Martha Walker, RD.

Coordinating center {#jbm410086-sec-0019}
-------------------

[Wake Forest University:]{.ul} Mark A. Espeland, PhD^1^; Judy L. Bahnson, BA, CCRP^3^; Lynne E. Wagenknecht, DrPH^1^; David Reboussin, PhD^3^; W. Jack Rejeski, PhD^3^; Alain G. Bertoni, MD, MPH^3^; Wei Lang, PhD^3^; David Lefkowitz, MD^3\*^ Patrick S. Reynolds, MD^3^; Denise Houston, PhD^3^; Mike E. Miller, PhD^3^; Laura D. Baker, PhD^3^; Nicholas Pajewski, PhD^3^; Stephen R. Rapp, PhD^3^; Stephen Kritchevsky, PhD^3^; Haiying Chen, PhD, MM^3^; Valerie Wilson, MD^3^; Delia S. West, PhD^3^; Ron Prineas, MD^3^; Tandaw Samdarshi, MD^3^; Amelia Hodges, BS, CCRP^2^; Karen Wall^2^; Carrie C. Williams, MA, CCRP^2^; Andrea Anderson, MS; Jerry M. Barnes, MA; Tara D. Beckner; Delilah R. Cook; Valery S. Effoe, MD, MS; Melanie Franks, BBA; Katie Garcia, MS; Sarah A. Gaussoin, MS; Candace Goode; Michelle Gordon, MS; Lea Harvin, BS; Mary A. Hontz, BA; Don G. Hire, BS; Patricia Hogan, MS; Mark King, BS; Kathy Lane, BS; Rebecca H. Neiberg, MS; Julia T. Rushing, MS; Debbie Steinberg, BS; Jennifer Walker, MS; Michael P. Walkup, MS.

Central resources centers {#jbm410086-sec-0020}
-------------------------

[Central Laboratory, Northwest Lipid Metabolism and Diabetes Research Laboratories:]{.ul} Santica M. Marcovina, PhD, ScD^1^; Jessica Hurting^2^; John J. Albers, PhD^3^, Vinod Gaur, PhD^4^.

[ECG Reading Center, EPICARE, Wake Forest University School of Medicine:]{.ul}

Elsayed Z. Soliman MD, MSc, MS^1^; Charles Campbell ^2^; Zhu‐Ming Zhang, MD^3^; Mary Barr; Susan Hensley; Julie Hu; Lisa Keasler; Yabing Li, MD.

[Hall‐Foushee Communications, Inc.:]{.ul} Richard Foushee, PhD; Nancy J. Hall, MA.

Federal Sponsors

[National Institute of Diabetes and Digestive and Kidney Diseases:]{.ul} Mary Evans, PhD; Van S. Hubbard, MD, PhD; Susan Z. Yanovski, MD.

[National Heart, Lung, and Blood Institute:]{.ul} Lawton S. Cooper, MD, MPH; Peter Kaufman, PhD, FABMR; Mario Stylianou, PhD.

[Centers for Disease Control and Prevention:]{.ul} Edward W. Gregg, PhD; Ping Zhang, PhD.

^1^Principal Investigator.

^2^Program Coordinator.

^3^Co‐Investigator.

All other Look AHEAD staff members are listed alphabetically by site.
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